1985PubMedRequires access

[VM-26 salvage therapy for refractory or recurrent germinal testicular cancers].

Takashi MIKI, Hiroki Oda, Shinji Saiki, T Kinouchi, Mitsugu Kuroda, Hiroki Kiyohara, Masaaki Usami, Takeshi Kotake

Open publisher page 0 citations

Abstract

Four patients with refractory or recurrent germinal testicular cancers were treated with the combination of VM-26 and cis-platinum, and two of them also in combination with radiation therapy. Two complete responses and two partial responses were observed. One partial response was rendered no evidence of disease by sequential radiation therapy. Three of the patients remained to have no evidence of disease from 16, 21 and 22 months. Toxicity was tolerable. VM-26 is an active drug in germinal testicular cancers and plays an important role in salvage therapy, for refractory or recurrent cases.

About this research paper

What this paper is about

Four patients with refractory or recurrent germinal testicular cancers were treated with the combination of VM-26 and cis-platinum, and two of them also in combination with radiation therapy. Two complete responses and two partial responses were observed. One partial response was rendered no evidence of disease by sequential radiation therapy. Three of the patients remained to have no evidence of disease from 16, 21 and 22 months. Toxicity was tolerable. VM-26 is an active drug in germinal testicular cancers and plays an important role in salvage therapy, for refractory or recurrent cases.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Four patients with refractory or recurrent germinal testicular cancers were treated with the combination of VM-26 and cis-platinum, and two of them also in combination with radiation therapy. Two complete responses and two partial responses were observed. One partial response was rendered no evidence of disease by sequential radiation therapy. Three of the patients remained to have no evidence of disease from 16, 21 and 22 months. Toxicity was tolerable. VM-26 is an active drug in germinal testicular cancers and plays an important role in salvage therapy, for refractory or recurrent cases.

Key concepts: Refractory (planetary science), Salvage therapy, Medicine, Radiation therapy, Complete response, Oncology, Combination therapy, Internal medicine

Related papers

Back to paper searchBrowse research topicsOriginal source
[VM-26 salvage therapy for refractory or recurrent germinal testicular cancers]. — Research Paper | ScholarLens